Hospital Severo Ochoa-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  2. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424

2006

  1. Polymorphisms in DNA repair genes modulate survival in cisplatin/ gemcitabine-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 17, Núm. 4, pp. 668-675